www.bjcancer.com

Short Communication

Epstein–Barr virus serology and gastric cancer incidence and survival

J Koshiol^{*,1,2}, Y-L Qiao³, SD Mark⁴, SM Dawsey², CC Abnet², F Kamangar², ET Lennette⁵, Z-W Dong³ and PR Taylor²

¹ Cancer Prevention Fellowship, Division of Cancer Prevention, National Cancer Institute, 6 I 20 Executive Blvd., MSC 7236, Bethesda, MD, USA; ²Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA; ³Cancer Institute, Chinese Academy of Medical Sciences, Beijing, People's Republic of China; ⁴Department of Preventive Medicine and Biometrics, University of Colorado Medical Center, Boulder, CO, USA; ⁵Nectandra Institute, San Ramon, Costa Rica

Among 185 cases of gastric cancer and 200 controls in Linxian, China, Epstein–Barr virus (EBV) seropositivity was not associated with increased risk of gastric cancer. High EBV nuclear antigen titres were associated with longer survival in cardia cancer cases, possibly due to chance.

British Journal of Cancer (2007) **97,** 1567–1569. doi:10.1038/sj.bjc.6604063 www.bjcancer.com Published online 6 November 2007 © 2007 Cancer Research UK

Keywords: EBV; gastric cancer; incidence; survival

Epstein – Barr virus (EBV), an established cause of lymphoma and nasopharyngeal carcinoma, has been detected in approximately 10% of gastric tumours (Young and Rickinson, 2004), leading to speculation that it may also cause gastric cancer.

Previous studies relating EBV to gastric cancer have primarily been tumour-based. The only previous study of prediagnostic EBV serology and gastric cancer incidence (Levine *et al*, 1995) found generally elevated odds ratios (ORs) for EBV seropositivity and gastric cancer, but included only 46 cases. No previous study has evaluated prediagnostic EBV serology and gastric cancer survival.

We prospectively evaluated the associations between baseline EBV serology in relation to (1) subsequent gastric cancer and (2) survival among gastric cancer patients in the Linxian General Population Nutrition Intervention Trial (NIT) cohort in China.

MATERIALS AND METHODS

The NIT was a cancer chemoprevention trial in Linxian, China, conducted from March 1986 through May 1991, that enrolled 29584 participants (Blot *et al*, 1993). Follow-up for additional survival is available through May 2001 (Tran *et al*, 2005). We analysed the relation of baseline EBV seropositivity to gastric cancer incidence in a nested case – control study of cardia cancer cases (N = 102, a random sample of the 435 cases that arose during the trial period), non-cardia cancer cases (N = 83), and randomly selected controls (N = 200). Case and control selection methods have been described elsewhere (Mark *et al*, 2000). We also analysed the association between EBV seropositivity and survival among gastric cancer cases.

*Correspondence: Dr J Koshiol; E-mail: koshiolj@mail.nih.gov Received I 3 August 2007; revised 3 October 2007; accepted 8 October 2007; published online 6 November 2007 We tested for IgA antibodies against the EBV viral capsid antigen (VCA IgA) and the diffuse early antigen (EA-D IgA), and for IgG antibodies against the EBV viral capsid antigen (VCA IgG), diffuse early antigen (EA-D IgG), restricted early antigen (EA-R IgG), and EBV nuclear antigen complex (EBNA) using immunofluorescence assays, as previously described (Levine *et al*, 1995). EA-D IgA was not detectable. EBV VCA IgA, EA-D IgG, and EA-R IgG antibodies were detected in <15% of cases and controls and so were categorised as positive or negative. EBV VCA IgG and EBNA antibodies, which were detectable in all subjects, were classified as high if above the median category of antibody titres in controls and low otherwise. VCA IgG antibody titres were also analysed ordinally.

Unconditional logistic regression was used to calculate ORs and 95% confidence intervals (CIs) for prediagnostic EBV serostatus and gastric cancer, controlling for age and gender. Other potential confounders (e.g., smoking, alcohol, *Helicobacter pylori*) were considered but did not affect the estimate for VCA IgG. Kaplan-Meier curves and age- and gender-adjusted Cox models were used to evaluate gastric cancer survival by baseline VCA IgG and EBNA.

RESULTS

Cases tended to be older than controls and were more likely to be males, smokers, and HP positive (Table 1). Among all subjects, EBV VCA IgA was detectable in 2%, EA-D IgG in 14%, and EA-R IgG in 9%. VCA IgG EBNA and antibody titre levels were above the median in the controls in 37% of all subjects.

Overall, prediagnostic EBV seropositivity was not positively associated with gastric cancer in this population (Table 2). In fact, the direction and magnitude of the associations suggested that EBV seropositivity was associated with decreased risk, especially tumours originating in the gastric cardia. A restricted analysis of

1568

cases diagnosed ≥ 2 years after serology strengthened the association for high VCA IgG but not EBNA.

There was no difference in survival by VCA IgG. Survival was longer among individuals with high vs low EBNA (hazard ratio (HR): 0.71, 95% CI: 0.51–0.98). This difference was found in cardia (HR: 0.46, 95% CI: 0.29–0.74) but not in non-cardia cancer cases (HR: 1.18, HR: 0.74–1.88) (Figure 1). Using the likelihood ratio test for multiplicative interaction, the HR for baseline EBNA seropositivity and gastric cancer varied by tumour location (*P*-value = 0.03). It is relevant to note, however, that the data become sparse in the tails of the survival curves, so these findings may be due to chance.

DISCUSSION

We found that prediagnostic EBV seropositivity was not positively associated with gastric cancer in this population and rather may be associated with decreased risk, especially for gastric cardia cancer which, unusually, is more common than non-cardia gastric cancer in Linxian (Blot *et al*, 1993). High baseline EBNA titres were also associated with decreased risk of death after diagnosis among gastric cardia cancer cases. Since EBV seropositivity is established

 Table I
 Selected characteristics and univariate associations with gastric cancer for nested case-control subjects from the General Population Nutrition Intervention Trial cohort

Characteristic	N Cases (%)	N Controls (%)
Age (years) <50 50-60 >60	32 (17.3) 79 (42.7) 74 (40.0)	58 (29.0) 68 (34.0) 74 (37.0)
Gender Male Female	113 (61.1) 72 (38.9)	98 (49.0) 102 (51.0)
Smoking (regularly for ≥6 months) No Yes	102 (55.1) 83 (44.9)	39 (69.5) 6 (30.5)
Alcohol (in last 12 months) Never/rare Sometimes/more often	143 (77.3) 42 (22.7)	160 (80.0) 40 (20.0)
Helicobacter pylori ^a Negative Positive	48 (27.8) 125 (72.3)	73 (45.3) 88 (54.7)

^aNumbers do not add up to totals because of missing values.

by both viral activity and immune response, these associations may reflect an increased immune response due to viral infection leading to reduced gastric cancer incidence and longer survival.

In contrast to our study, the only previous prospective study reported generally elevated ORs, suggesting an increased risk of gastric cancer with EBV seropositivity (Levine *et al*, 1995). The opposite patterns of risk found in these two studies may be due to (1) chance, with no true underlying association, (2) differences in study populations, or (3) different distributions of tumour location since the previous study included few gastric cardia cancers, while over half the cases in our study had cardia cancer.

Although previous studies of EBV DNA in gastric tumour tissue and survival have produced inconsistent results (Chang *et al*, 2001; Lee *et al*, 2004), some have found improved survival associated with EBV, at least in subgroups (Koriyama *et al*, 2002; Lee *et al*, 2004; van Beek *et al*, 2004). Our association between high EBNA titres and improved survival was also limited to a subgroup, cardia cancers, although this finding may be due to chance. Further, we did not have tumour tissue available to directly test for EBV DNA.

In conclusion, we did not find a positive association between prediagnostic EBV seropositivity and gastric cancer. In fact, there was some evidence that EBV seropositivity was associated with a reduced risk of cancer and a reduced risk of death after diagnosis of cardia cancer. These results support the hypothesis that cardia and non-cardia cancers may be aetiologically different and should be evaluated separately in future studies.



Figure I Kaplan–Meier curves for the proportion of gastric cancer cases remaining alive by baseline EBV EBNA serostatus and tumour location.

 Table 2
 Association between prediagnostic EBV seropositivity and development of gastric cancer in the General Population Nutrition Intervention Trial cohort for all cases combined and stratified by tumour location

EBV variable	All cases (n = 185)		Cardia (n = 102)		Non-cardia (n = 83)	
	N positive cases	OR (95% CI) ^a	N positive cases	OR (95% CI) ^a	N positive cases	OR (95% CI) ^a
VCA IgA positive	3	0.69 (0.15-3.21)	I	0.46 (0.05-4.20)	2	0.90 (0.15-5.40)
EA-D IgG positive	26	0.95 (0.53–1.70)	13	0.82 (0.41–1.67)	13	1.23 (0.58-2.60)
EA-R IgG positive	11	0.52 (0.24-1.11)	6	0.49 (0.19-1.23)	5	0.55 (0.19-1.57)
High VCA IgG ^b	60	0.72 (0.47-1.09)	32	0.63 (0.38-1.05)	28	0.83 (0.47-1.46)
Restricted ^c	32	0.60 (0.36-0.99)	19	0.54 (0.30-0.99)	13	0.70 (0.33-1.46)
High EBNA IgG	67	0.91 (0.60-1.39)	38	0.97 (0.59 – 1.60)	29	0.79 (0.45 – 1.39)
Restricted	42	1.01 (0.62–1.64)	26	I.03 (0.59–I.83)	16	0.90 (0.44–1.84)

^aAdjusted for age and gender. ^bOdds ratios (ORs) for ordinal VCA lgG: all cases, 0.89 (0.78 – 1.02); cardia cases, 0.86 (0.74 – 1.00); non-cardia cases, 0.96 (0.80 – 1.14). ^cRestricted to cases diagnosed after 2 years of follow-up.

REFERENCES

- Blot WJ, Li JY, Taylor PR, Guo W, Dawsey S, Wang GQ, Yang CS, Zheng SF, Gail M, Li GY, Yu Y, Liu B, Tangrea J, Sun Y, Liu F, Fraumeni JF, Zhang YH, Li B (1993) Nutrition intervention trials in Linxian, China: supplementation with specific vitamin/mineral combinations, cancer incidence, and disease-specific mortality in the general population. *J Natl Cancer Inst* **85**: 1483–1492
- Chang MS, Lee HS, Kim CW, Kim YI, Kim WH (2001) Clinicopathologic characteristics of Epstein-Barr virus-incorporated gastric cancers in Korea. *Pathol Res Pract* **197**: 395-400
- Koriyama C, Akiba S, Itoh T, Kijima Y, Sueyoshi K, Corvalan A, Herrera-Goepfer R, Eizuru Y (2002) Prognostic significance of Epstein-Barr virus involvement in gastric carcinoma in Japan. *Int J Mol Med* **10**: 635-639
- Lee HS, Chang MS, Yang HK, Lee BL, Kim WH (2004) Epstein Barr viruspositive gastric carcinoma has a distinct protein expression profile in comparison with Epstein – Barr virus-negative carcinoma. *Clin Cancer Res* **10**: 1698–1705

- Levine PH, Stemmermann G, Lennette ET, Hildesheim A, Shibata D, Nomura A (1995) Elevated antibody titers to Epstein – Barr virus prior to the diagnosis of Epstein – Barr-virus-associated gastric adenocarcinoma. Int J Cancer 60: 642–644
- Mark SD, Qiao YL, Dawsey SM, Wu YP, Katki H, Gunter EW, Fraumeni Jr JF, Blot WJ, Dong ZW, Taylor PR (2000) Prospective study of serum selenium levels and incident esophageal and gastric cancers. J Natl Cancer Inst 92: 1753 – 1763
- Tran GD, Sun XD, Abnet CC, Fan JH, Dawsey SM, Dong ZW, Mark SD, Qiao YL, Taylor PR (2005) Prospective study of risk factors for esophageal and gastric cancers in the Linxian general population trial cohort in China. Int J Cancer 113: 456-463
- van Beek J, zur Hausen A, Klein Kranenbarg E, van de Velde CJ, Middeldorp JM, van den Brule AJ, Meijer CJ, Bloemena E (2004) EBVpositive gastric adenocarcinomas: a distinct clinicopathologic entity with a low frequency of lymph node involvement. J Clin Oncol 22: 664-670
- Young LS, Rickinson AB (2004) Epstein Barr virus: 40 years on. Nat Rev 4: 757 768